louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03240367: Comparison of Stapler Line Bleeding Control Techniquessurgery
Official title: Comparison of Stapler Line Bleeding Control Techniques in Laparoscopic Gastric Bypass
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity, Morbid
Lead sponsor: Inonu University
Sponsor class: OTHER
First posted: 2017-08-07
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Introduction RYGB surgeon; Have become increasingly morbid obesity treatment methods with improvements in minimally invasive surgery. Ensuring patient comfort and early return to life are the criteria that should be given priority in this treatment method.The purpose of this study; Emphasizing that the cautery technique of the stapler line bleeding control methods is as successful as the other methods.

Detailed description: The question of the availability of cautery in RYGB surgeons

Eligibility criteria: Inclusion Criteria:

* Morbid obese patients

Exclusion Criteria:

* Cirrhotic patients, those under 18 years of age, additional intraabdominal surgeries during LRYGBP and those who had previously undergone obesity surgery (revision surgery)

Primary outcomes:
measure: 3-item drainage control
timeFrame: 8 months
Secondary outcomes:
Other outcomes:
Locations:
city: Malatya
country: Turkey
facility: Inonu University
Study officials:
affiliation: study principal investigator
name: Ersin Gündoğan, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01867567: Early Bandage Removal Post-Cesarean Delivery
Official title: Early Bandage Removal Post-Cesarean Delivery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Wound Disruption
Wound Infection
Keywords: cesarean
bandage removal
infection
disruption
satisfaction
patient satisfaction
Lead sponsor: Ziv Hospital
Sponsor class: OTHER_GOV
First posted: 2013-06-04
Enrollment: 320
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Women undergoing their first second or third cesarean section will be randomized into two groups. One group will have the abdominal bandage removed at 6 hours post-surgery and the other group will have the bandage removed at 24 hours. Staple removal will be at 5 - 7 days for both groups. The incision will be inspected at the time of staple removal. The 2 groups will be compared for incision disruption and infection. Also, the women will be asked about their satisfaction for time of bandage removal.


Eligibility criteria: Inclusion Criteria:

* age of 18 to 44
* elective cesarean section, primary or repeat
* low risk pregnancy

Exclusion Criteria:

* under the age of 18 and above the age of 44
* diabetes, preeclampsia or other pregnancy complications
* unable or unwilling to give informed consent
* chorioamnionitis
* BMI over 35
* more than 3 cesareans

Primary outcomes:
measure: Wound Disruption
timeFrame: 5 - 7 days
Secondary outcomes:
measure: Wound Infection
timeFrame: 5 - 7 days
measure: Patient satisfaction
timeFrame: 5 - 7 days
Other outcomes:
Locations:
city: Tsefat
country: Israel
facility: Ziv Medical center
Study officials:
References:
Clinical trial NCT00793767: Insulin Resistance and Substrate Metabolism After Acute Erythropoietin (EPO) Administration
Official title: Insulin Resistance and Substrate Metabolism After Acute EPO Administration in Healthy Young Men
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Insulin Sensitivity
Keywords: Erythropoietin
human muscle tissue
insulin sensitivity
substrate metabolism
Lead sponsor: Aarhus University Hospital
Sponsor class: OTHER
First posted: 2008-11-19
Enrollment: 10
Sex: MALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Recently EPO receptors have been found in human muscle tissue, but what is still not known is the physiological role of these receptors. In this study the researchers want to investigate if there is any effect of a acute administration of EPO on insulin resistance and/or substrate metabolism in muscle tissue.

Detailed description: Recently EPO receptors have been found in human muscle tissue, but what is still not known is what the physiological role of these receptors are. It has previously been shown that Growth Hormone mediate insulin resistance. The GH receptor and EPO receptor belong to the same family of cytokine receptors, and thereby share many of the same signalling pathways. In this study we want to investigate if there is a similar effect on insulin resistance and/or substrate metabolism after acute administration of EPO in human muscle tissue. Different signalling pathways are investigated på western blotting, and insulin sensitivity are measured be a hyperinsulinemic euglycemic clamp, and substrate metabolism is measured by the forearm model.

Eligibility criteria: Inclusion Criteria:

* Healthy persons
* Between 18 and 30 years
* Normal weight (BMI: 18-25)

Exclusion Criteria:

* Severe heart disease (NYHA 3)
* Uncontrolled hypertension
* Previous cerebrovascular disease
* Proliferative retinopathy
* Diabetes
* Musculo-skeletal diseases

Primary outcomes:
measure: Insulin sensitivity
timeFrame: 4 and 6 hours post
Secondary outcomes:
measure: Substrate metabolism
timeFrame: 4 and 6 hours post
Other outcomes:
Locations:
city: Århus C
country: Denmark
facility: Medicinsk forsknings laboratorium
Study officials:
References:
Clinical trial NCT03561467: Oral Chemotherapy and Quality of Care
Official title: Community and Hospital Experiences for Patients Treated by Oral Chemotherapy at the University Hospital of Caen: Analysis of the Process and Its Dysfunctions
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cancer
Lead sponsor: University Hospital, Caen
Sponsor class: OTHER
Collaborators: name: MSD France
First posted: 2018-06-19
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult outpatients treated by oral chemotherapy for a cancer disease

Brief summary: PARCOURS is a non-interventional research study evaluating dysfunctions in the continuous city-hospital journey of a patients cohort treated by oral chemotherapy (60 patients followed for 3 months).

References used are the National Cancer Institute recommendations for the oral chemotherapy treated outpatients.

Parameters found are : information exchanged, ambulatory and hospital monitoring in case of adverse event and adherence to treatment. The study includes also a medico-economic evaluation (hospitalization and transport spending in case of dysfunction in the patient's journey). Deviations will be analyzed.


Eligibility criteria: Inclusion Criteria:

* Patient over 18 years old
* Suffering from cancer (hematological malignancies, digestive tumors, thoracic tumors or cutaneous tumors)
* With an oral anticancer chemotherapy initial prescription written by an oncologist or hematologist from the University Hospital of Caen, whatever the place of the drug dispensing (Community pharmacy or hospital pharmacy )

Exclusion Criteria:

- Patient treated by oral anticancer chemotherapy for another pathology

Primary outcomes:
measure: Number of dysfunctions
timeFrame: 3 months
Secondary outcomes:
measure: Drug adherence
timeFrame: 3 months
measure: Drug adherence
timeFrame: 3 months
measure: Adverse events
timeFrame: 3 months
measure: Expenses related to the use of unplanned hospital care
timeFrame: 3 months
measure: Satisfaction of the patient
timeFrame: At month 3
measure: Satisfaction of the caregiver
timeFrame: At month 3
measure: Satisfaction of the local professionals
timeFrame: At month 3
measure: Quality of life of patients
timeFrame: At month 3
Other outcomes:
Locations:
city: Caen
country: France
facility: Caen University Hopsital
Study officials:
References:
Clinical trial NCT01933867: Water-aided Colonoscopy in Inflammatory Bowel Disease Patients
Official title: Water-aided Colonoscopy in Patients With Inflammatory Bowel Disease - a Single-center, Single-blinded Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Inflammatory Bowel Disease
Keywords: water
colonoscopy
Crohn´s disease
ulcerative colitis
Lead sponsor: Vitkovice Hospital
Sponsor class: OTHER
First posted: 2013-09-02
Enrollment: 92
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Water-aided insertion of the colonoscope has been repeatedly proven to beneficial in terms of lower discomfort and need for sedation during colonoscopy. Patients with inflammatory bowel diseases (IBD) undergo repeated colonoscopy in course of their disease. According to our preliminary experience, water immersion could be beneficial while scoping these patients. As far as the investigators know, water-aided colonoscopy has never been studied in this indication. Results of our trial might support use of water-aided colonoscopy in common practice and decrease associated discomfort in IBD patients.


Eligibility criteria: Inclusion Criteria:

* known diagnosis of inflammatory bowel disease
* planned diagnostic outpatient colonoscopy
* signed informed consent
* willingness to undergo unsedated colonoscopy

Exclusion Criteria:

* ulcerative proctitis
* bowel resection longer than ileocecal resection
* requirement for sedation

Primary outcomes:
measure: Success rate of unsedated colonoscopy
timeFrame: at the end of each colonoscopy
Secondary outcomes:
measure: Discomfort during colonoscopy
timeFrame: at the end of each colonoscopy
measure: Cecal intubation time
timeFrame: while reaching the cecum
Other outcomes:
Locations:
city: Ostrava
country: Czech Republic
facility: Digestive Diseases Center, Vitkovice Hospital
Study officials:
References:
citation: Falt P, Smajstrla V, Fojtik P, Urban O, Hill M. Water-Aided Colonoscopy in Inflammatory Bowel Disease Patients-A Randomised, Single-Centre Trial. J Crohns Colitis. 2015 Sep;9(9):720-4. doi: 10.1093/ecco-jcc/jjv093. Epub 2015 Jun 3.
Clinical trial NCT02708667: An Observational Research Of Crizotinib's Hepatic Toxicity In Non-small Cell Lung Cancer Patients
Official title: An Observational Research on Relationship Between c-Met Gene Polymorphism, Promoter Methylation Level, Related Drug Metabolism Enzymes and Crizotinib's Hepatic Toxicity in Non-small Cell Lung Cancer Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Non-Small Cell Lung Cancer
Keywords: non-small cell lung cancer
crizotinib
hepatic toxicity
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2016-03-15
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who were diagnosed with stage III or IV non-small cell lung cancer (NSCLC), harbored ALK fusion gene and took crizotinib.

Brief summary: Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), was approved by Food and Drug Administration (FDA) for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC) and its administration has achieved considerable success. However, adverse effects inevitably occurred and the most common one was hepatic toxicity, appearing as elevating alanine aminotransferase(ALT) and aspartate aminotransferase(AST). Therefore, the investigators try to figure out the mechanism of crizotinib-inducing hepatic toxicity, and explore whether there is any biological marker to diagnose this side effect in an early stage, which may realize individualized therapy with more efficacy and less side effects.


Eligibility criteria: Inclusion Criteria:

1. patients who were histologically and cytologically confirmed NSCLC at stage III or IV
2. harbored ALK fusion gene and took crizotinib
3. age:18\~75years
4. Eastern cooperative oncology group performance status(ECOG PS): 0\~2 points
5. the expected lifetime is more than 12 weeks after being recruited

Exclusion Criteria:

1. patients who also suffered from other malignant tumor
2. uncontrolled systemic diseases,central nervous system (CNS) metastasis
3. clinically active interstitial lung diseases
4. severe liver dysfunction caused by hepatic cirrhosis or hepatitis （Child-Pugh class C, total index score 10-15 points）
5. taking drugs that interact with crizotinib

Primary outcomes:
measure: number of patients with adverse events
timeFrame: change from the date of taking crizotinib at 9 months
Secondary outcomes:
measure: progression free survival
timeFrame: from the date of taking crizotinib to the date of objective tumor progression or date of death from any cause,whichever came first,assessed up to 48 months
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen University Cancer Center
state: Guangdong
Study officials:
affiliation: Sun Yat-sen University
name: Likun Chen
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01849367: Trial of Bilateral tDCS for Depression
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Depression
Lead sponsor: The University of New South Wales
Sponsor class: OTHER
First posted: 2013-05-08
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Transcranial direct current stimulation (tDCS) is a novel treatment approach for depression that has shown promising efficacy in four recent double-blind, randomized, sham-controlled trials (RCT) and a meta-analysis. Mood, cognitive test performance and biomarkers will be measured during the trial.


Eligibility criteria: Inclusion Criteria:

1. Participant meets criteria for a DSM-IV Major Depressive episode.
2. MADRS score of 20 or more.

Exclusion Criteria:

1. Diagnosis (as defined by DSM-IV) of: any psychotic disorder (lifetime); eating disorder (current or within the past year); obsessive compulsive disorder (lifetime); post-traumatic stress disorder (current or within the past year); mental retardation.
2. History of drug or alcohol abuse or dependence (as per DSM-IV criteria) within the last 3 months (except nicotine and caffeine).
3. Inadequate response to ECT in the current episode of depression.
4. Participant is on regular benzodiazepine medication which is not clinically appropriate to discontinue.
5. Participant requires a rapid clinical response due to inanition, psychosis or high suicide risk.
6. Neurological disorder or insult, e.g., recent stroke (CVA), which places participant at risk of seizure or neuronal damage with tDCS.
7. Participant has metal in the cranium, skull defects, or skin lesions on scalp (cuts, abrasions, rash) at proposed electrode sites.
8. Female participant who is pregnant, or of child-bearing age, sexually active and not using reliable contraception (urine test for pregnancy will be used).
9. Participants who are not fluent in English will not be included in the trial for safety reasons.

Primary outcomes:
measure: Montgomery Asberg Depression Rating Scale for Depression (MADRS)
timeFrame: 4 weeks
Secondary outcomes:
measure: Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Sydney
country: Australia
facility: Black Dog Institute / University of New South Wales
state: New South Wales
Study officials:
References:
Clinical trial NCT06980467: Evaluation of AI-Generated Clinical Advice by Physicians
Official title: A Study on the Evaluation of Artificial Intelligence-Generated Clinical Advisory Outputs in Medical Professional Contexts
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Artificial Intelligence (AI)
Lead sponsor: Tsinghua University
Sponsor class: OTHER
First posted: 2025-05-20
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: This study examines how artificial intelligence systems interact with medical professionals. Researchers will compare physician responses to different AI-generated outputs in simulative medical scenarios.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years old;
* Licensed physician or medical professional qualified to perform clinical evaluations;
* Willing to sign informed consent and commit time to participate in the study.

Exclusion Criteria:

* Unable to dedicate sufficient time to complete the study tasks;
* Unable or unwilling to understand and follow study instructions.

Primary outcomes:
measure: Physician Response to AI-Generated Medical Content
timeFrame: Through study completion, an average of 1 week
Secondary outcomes:
measure: Physician Perception of Communication Quality in AI-Generated Content
timeFrame: Through study completion, an average of 1 week
Other outcomes:
Locations:
city: Beijing
country: China
facility: Tsinghua University
state: Beijing
city: Wu Xi
country: China
facility: Shanghai Health and Medical Center
state: Jiang Su
Study officials:
References:
Clinical trial NCT01088867: Using Diffuse Noxious Inhibitory Control (DNIC) to Predict Acupuncture Therapy Outcome: A Pilot Study
Official title: Using DNIC to Predict Acupuncture Therapy Outcome: A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain
Keywords: Pain
Acupuncture
DNIC
Electroacupuncture
Lead sponsor: University of Washington
Sponsor class: OTHER
Collaborators: name: Bastyr University
First posted: 2010-03-17
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: The investigators hypothesize that acupuncture modifies the DNIC efficiency and that DNIC can serve as a predictor to identify 'good responders' to acupuncture early in therapy.


Eligibility criteria: Inclusion Criteria:

* Healthy women with a progesterone-coated intrauterine device (Mirena), and
* Men greater than or equal to 18 years old.

Exclusion Criteria:

* Acupuncture treatment in the previous six weeks, to discount any persisting effect of acupuncture.
* Treatment of a pain condition with pain medication.
* Regular use of benzodiazepines.
* Skin diseases, such as scleroderma, psoriasis or eczema.
* An adverse event due to acupuncture therapy.
* Pregnant women.
* Women without a progesterone-coated intrauterine device (Mirena).
* Anyone older than 60 years of age, fatigued, with a pacemaker ICD, artificial joint, prolonged bleeding time/hemophilia, open wounds, or a known susceptibility to profound analgesia after acupuncture treatment.

Primary outcomes:
measure: Diffuse Noxious Inhibitory Control Efficiency
timeFrame: Week 0, 2, 4, 6, and 12 of acupuncture therapy
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: University of Washington
state: Washington
Study officials:
affiliation: University of Washington
name: Ruth Landau, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04342767: The Effectiveness of a Mechanical Debridement Instrument in Reducing Bioburden in Chronic Wounds
Official title: The Effectiveness of a Mechanical Debridement Instrument in Reducing Bioburden in Chronic Wounds
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Wounds
Chronic Wounds
Lead sponsor: SerenaGroup, Inc.
Sponsor class: NETWORK
Collaborators: name: MDM Wound Ventures, LLC
First posted: 2020-04-13
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with acute or chronic wounds

Brief summary: This prospective clinical trial will compare the bacterial burden in the wound bed and on the periwound skin before and after mechanical debridement with EZ Debride using fluorescence imaging.

After consenting, the ulcers of eligible subjects are measured, photographed and undergo the MolecuLight imaging procedure (MLiX). The ulcer is mechanically debridement with the EZ Debride device after which a second MLiX procedure is performed. The investigator will then compare the two images.

Detailed description: Acute and chronic wounds burden healthcare systems across the globe. In the United States the cost of nonhealing wounds approximates 100 billion dollars.1-3 The presence of bacteria in and around the wound impedes wound healing. Clinicians treat elevated wound bacterial levels with mechanical and sharp debridement, topical antiseptics and systemic antibiotics. However, evidence on the best methods to reduce bacterial load is lacking. The EZ-1 clinical trial will utilize the latest fluorescence imaging technology to investigate whether mechanical debridement using the EZ Debride® tool reduces bacterial burden.

Eligibility criteria: Inclusion Criteria:

1. Adult patients with acute or chronic wounds that have been present for a minimum of 4 weeks.
2. A signed and dated informed consent form.
3. Subject is willing and able to comply with instructions and scheduled visits.

Exclusion Criteria:

1. The Subject has other concurrent conditions that in the opinion of the Investigator may compromise subject safety.
2. The subject's wound has not been present for at least 4 weeks.

Primary outcomes:
measure: Change in Bacterial Bioburden
timeFrame: Before and After Mechanical debridement within 1 hour
Secondary outcomes:
measure: Pain Score
timeFrame: Before, during, and after mechanical debridement within 1 hour
measure: Adverse Events
timeFrame: During debridement
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: Serena Group Research Institute
state: Pennsylvania
Study officials:
affiliation: SerenaGroup, Inc.
name: Thomas E Serena, MD,FACS
role: PRINCIPAL_INVESTIGATOR
References: